中国科学院机构知识库网格
Chinese Academy of Sciences Institutional Repositories Grid
首页
机构
成果
学者
登录
注册
登陆
×
验证码:
换一张
忘记密码?
记住我
×
校外用户登录
CAS IR Grid
机构
化学研究所 [14]
上海药物研究所 [11]
高能物理研究所 [4]
西安光学精密机械研究... [4]
成都生物研究所 [2]
长春光学精密机械与物... [1]
更多
采集方式
OAI收割 [40]
iSwitch采集 [1]
内容类型
期刊论文 [35]
专利 [5]
学位论文 [1]
发表日期
2023 [1]
2022 [3]
2021 [3]
2020 [3]
2019 [1]
2018 [3]
更多
学科主题
天然产物研究 [2]
筛选
浏览/检索结果:
共41条,第1-10条
帮助
条数/页:
5
10
15
20
25
30
35
40
45
50
55
60
65
70
75
80
85
90
95
100
排序方式:
请选择
提交时间升序
提交时间降序
题名升序
题名降序
作者升序
作者降序
发表日期升序
发表日期降序
Discovery of HCD3514 as a potent EGFR inhibitor against C797S mutation in vitro and in vivo
期刊论文
OAI收割
JOURNAL OF CANCER, 2023, 卷号: 14, 期号: 1, 页码: 152-162
作者:
Lai, Mengzhen
;
Zhang, Tao
;
Chen, Hao
;
Song, Peiran
;
Tong, Linjiang
  |  
收藏
  |  
浏览/下载:111/0
  |  
提交时间:2023/04/10
fourth-generation EGFR inhibitor
EGFRC797S mutation
NSCLC
drug resistance
small molecular inhibitor
Discovery of 3-Aminopyrazole Derivatives as New Potent and Orally Bioavailable AXL Inhibitors
期刊论文
OAI收割
JOURNAL OF MEDICINAL CHEMISTRY, 2022, 卷号: 65, 期号: 22, 页码: 15374-15390
作者:
Chan, Shingpan
;
Zhang, Yunong
;
Wang, Jie
;
Yu, Qiuchun
;
Peng, Xia
  |  
收藏
  |  
浏览/下载:16/0
  |  
提交时间:2023/04/10
Conformational Constrained 4-(1-Sulfonyl-3-indol)yl-2-phenylaminopyrimidine Derivatives as New Fourth-GenerationEpidermal Growth Factor Receptor Inhibitors Targeting T790M/C797S Mutations br
期刊论文
OAI收割
JOURNAL OF MEDICINAL CHEMISTRY, 2022, 卷号: 65, 期号: 9, 页码: 6840-6858
作者:
Chen, Hao
;
Lai, Mengzhen
;
Zhang, Tao
;
Chen, Yuqing
;
Tong, Linjiang
  |  
收藏
  |  
浏览/下载:23/0
  |  
提交时间:2022/08/16
Optimization of Brigatinib as New Wild-Type Sparing Inhibitors of EGFR(T790M/C797S) Mutants
期刊论文
OAI收割
ACS MEDICINAL CHEMISTRY LETTERS, 2022, 页码: 7
作者:
Li, Shan
;
Zhang, Tao
;
Zhu, Su-Jie
;
Lei, Chong
;
Lai, Mengzhen
  |  
收藏
  |  
浏览/下载:25/0
  |  
提交时间:2022/06/15
Epidermal Growth Factor Receptor (EGFR)
Resistant Mutation
C797S
Antitumor
LS-106, a novel EGFR inhibitor targeting C797S, exhibits antitumor activities both in vitro and in vivo
期刊论文
OAI收割
CANCER SCIENCE, 2021, 页码: 12
作者:
Liu, Yingqiang
;
Lai, Mengzhen
;
Li, Shan
;
Wang, Yanan
;
Feng, Fang
  |  
收藏
  |  
浏览/下载:87/0
  |  
提交时间:2022/01/18
C797S
epidermal growth factor receptor
fourth-generation EGFR TKI
non-small cell lung cancer
osimertinib resistance
Discovery of a novel third-generation EGFR inhibitor and identification of a potential combination strategy to overcome resistance (vol 19, 90, 2020)
期刊论文
OAI收割
MOLECULAR CANCER, 2021, 卷号: 20, 期号: 1, 页码: 1
作者:
Zhang, Tao
;
Qu, Rong
;
Chan, Shingpan
;
Lai, Mengzhen
;
Tong, Linjiang
  |  
收藏
  |  
浏览/下载:87/0
  |  
提交时间:2021/11/04
Correction to: Discovery of a novel third-generation EGFR inhibitor and identification of a potential combination strategy to overcome resistance
期刊论文
OAI收割
Molecular Cancer, 2021, 卷号: 20, 期号: 1
作者:
Zhang,Tao
;
Qu,Rong
;
Chan,Shingpan
;
Lai,Mengzhen
;
Tong,Linjiang
  |  
收藏
  |  
浏览/下载:61/0
  |  
提交时间:2021/11/04
Discovery of a novel third-generation EGFR inhibitor and identification of a potential combination strategy to overcome resistance
期刊论文
OAI收割
MOLECULAR CANCER, 2020, 卷号: 19, 期号: 1, 页码: 15
作者:
Zhang, Tao
;
Qu, Rong
;
Chan, Shingpan
;
Lai, Mengzhen
;
Tong, Linjiang
  |  
收藏
  |  
浏览/下载:79/0
  |  
提交时间:2020/07/01
Non-small cell lung cancer (NSCLC)
EGFR T790M
Small-molecule inhibitor
Drug resistance
Ack1
2-Oxo-3,4-dihydropyrimido[4,5-d] pyrimidines as new reversible inhibitors of EGFR C797S (Cys797 to Ser797) mutant
期刊论文
OAI收割
CHINESE CHEMICAL LETTERS, 2020, 卷号: 31, 期号: 5, 页码: 1281-1287
作者:
Hu, Xianglong
;
Xun, Qiuju
;
Zhang, Tao
;
Zhu, Su-Jie
;
Li, Qian
  |  
收藏
  |  
浏览/下载:81/0
  |  
提交时间:2020/07/01
EGFR(C797S) mutant
SARs
2-Oxo-3,4-dihydropyrimido[4,5-d] pyrimidine
Clinical resistance
Fourth-generation inhibitors
Design and synthesis of selective degraders of EGFR(L858R/T790M) mutant
期刊论文
OAI收割
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2020, 卷号: 192, 页码: 14
作者:
Zhang, Xin
;
Xu, Fang
;
Tong, Linjiang
;
Zhang, Tao
;
Xie, Hua
  |  
收藏
  |  
浏览/下载:68/0
  |  
提交时间:2020/07/01
Epidermal growth factor receptor (EGFR)
Resistance
Proteolysis targeting chimera (PROTAC)
Protein degradation